Corcept Therapeutics Inc. (NASDAQ:CORT) Director Patrick G. Enright sold 174,847 shares of the company’s stock in a transaction that occurred on Wednesday, November 16th. The shares were sold at an average price of $9.55, for a total value of $1,669,788.85. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Shares of Corcept Therapeutics Inc. (NASDAQ:CORT) opened at 9.45 on Monday. Corcept Therapeutics Inc. has a 1-year low of $3.22 and a 1-year high of $10.00. The company has a 50 day moving average price of $7.46 and a 200 day moving average price of $6.09. The stock has a market cap of $1.05 billion, a P/E ratio of 242.31 and a beta of 1.64.

Insider Buying and Selling by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Several hedge funds and other institutional investors have recently made changes to their positions in CORT. D.A. Davidson & CO. raised its position in shares of Corcept Therapeutics by 119.8% in the third quarter. D.A. Davidson & CO. now owns 192,634 shares of the company’s stock valued at $1,252,000 after buying an additional 105,000 shares during the period. Panagora Asset Management Inc. raised its position in shares of Corcept Therapeutics by 352.8% in the third quarter. Panagora Asset Management Inc. now owns 47,032 shares of the company’s stock valued at $305,000 after buying an additional 36,645 shares during the period. D. E. Shaw & Co. Inc. raised its position in shares of Corcept Therapeutics by 30.8% in the third quarter. D. E. Shaw & Co. Inc. now owns 141,784 shares of the company’s stock valued at $921,000 after buying an additional 33,351 shares during the period. Gotham Asset Management LLC raised its position in shares of Corcept Therapeutics by 39.2% in the third quarter. Gotham Asset Management LLC now owns 20,908 shares of the company’s stock valued at $136,000 after buying an additional 5,884 shares during the period. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Corcept Therapeutics during the third quarter valued at about $351,000. Institutional investors and hedge funds own 41.24% of the company’s stock.

Several research analysts have recently issued reports on the company. FBR & Co set a $12.00 target price on Corcept Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, November 2nd. Zacks Investment Research lowered Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 27th. Finally, Piper Jaffray Cos. set a $12.00 target price on Corcept Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, October 19th.

Corcept Therapeutics Company Profile

Corcept Therapeutics Inc is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company’s focus is on those disorders that are associated with a steroid hormone cortisol. Elevated levels and abnormal release patterns of cortisol have been implicated in a range of human disorders.

5 Day Chart for NASDAQ:CORT

Receive News & Stock Ratings for Corcept Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics Inc. and related stocks with our FREE daily email newsletter.